-
EP3773715
European procedure
Extract from the Register of European Patents
EP About this file: EP3773715
| EP3773715 - MIRIKIZUMAB IN THE TREATMENT OF ULCERATIVE COLITIS [Right-click to bookmark this link] | |||
| Former [2021/07] | METHODS OF TREATING ULCERATIVE COLITIS | ||
| [2023/15] | Status | No opposition filed within time limit Status updated on 14.03.2025 Database last updated on 01.04.2026 | |
| Former | The patent has been granted Status updated on 05.04.2024 | ||
| Former | Grant of patent is intended Status updated on 17.03.2024 | ||
| Former | Examination is in progress Status updated on 05.02.2024 | ||
| Former | Grant of patent is intended Status updated on 03.10.2023 | ||
| Former | Examination is in progress Status updated on 08.09.2023 | ||
| Former | Grant of patent is intended Status updated on 10.05.2023 | ||
| Former | Examination is in progress Status updated on 06.08.2021 | ||
| Former | Request for examination was made Status updated on 15.01.2021 | ||
| Former | The international publication has been made Status updated on 05.10.2019 | ||
| Former | unknown Status updated on 15.05.2019 | Most recent event Tooltip | 14.03.2025 | No opposition filed within time limit | published on 16.04.2025 [2025/16] | Applicant(s) | For all designated states Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US | [2021/07] | Inventor(s) | 01 /
CANAVAN, James Benedict c/o ELI LILLY AND COMPANY P.O. Box 6288 Indianapolis, Indiana 46206-6288 / US | 02 /
FRIEDRICH, Stuart William c/o ELI LILLY AND COMPANY P.O. Box 6288 Indianapolis, Indiana 46206-6288 / US | 03 /
KRUEGER, Kathryn Ann c/o ELI LILLY AND COMPANY P.O. Box 6288 Indianapolis, Indiana 46206-6288 / US | 04 /
MILCH, Catherine c/o ELI LILLY AND COMPANY P.O. Box 6288 Indianapolis, Indiana 46206-6288 / US | 05 /
TUTTLE, Jay Lawrence c/o ELI LILLY AND COMPANY P.O. Box 6288 Indianapolis, Indiana 46206-6288 / US | [2021/07] | Representative(s) | Boanas-Evans, Duncan Richard Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | [2024/19] |
| Former [2021/07] | O'Connor, David, et al Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | Application number, filing date | 19722256.5 | 28.03.2019 | [2021/07] | WO2019US24633 | Priority number, date | US201862650314P | 30.03.2018 Original published format: US 201862650314 P | [2021/07] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019191464 | Date: | 03.10.2019 | Language: | EN | [2019/40] | Type: | A1 Application with search report | No.: | EP3773715 | Date: | 17.02.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 03.10.2019 takes the place of the publication of the European patent application. | [2021/07] | Type: | B1 Patent specification | No.: | EP3773715 | Date: | 08.05.2024 | Language: | EN | [2024/19] | Search report(s) | International search report - published on: | EP | 03.10.2019 | Classification | IPC: | A61K39/395, C07K16/24, A61P1/04 | [2023/18] | CPC: |
C07K16/244 (EP,IL,KR,US);
A61K9/0019 (IL,US);
A61P1/04 (EP,IL,KR,US);
A61K2039/505 (EP,IL,KR);
A61K2039/545 (IL,KR)
|
| Former IPC [2023/15] | C07K16/00, A61K39/395 | ||
| Former IPC [2021/07] | A61K39/395 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/07] | Extension states | BA | 30.10.2020 | ME | 30.10.2020 | Validation states | MA | 30.10.2020 | MD | 30.10.2020 | TN | 30.10.2020 | Title | German: | MIRIKIZUMAB ZUR BEHANDLUNG VON COLITIS ULCEROSA | [2023/15] | English: | MIRIKIZUMAB IN THE TREATMENT OF ULCERATIVE COLITIS | [2023/15] | French: | MIRIKIZUMAB POUR LE TRAITEMENT DE LA COLITE ULCÉREUSE | [2023/15] |
| Former [2021/07] | VERFAHREN ZUR BEHANDLUNG VON COLITIS ULCEROSA | ||
| Former [2021/07] | METHODS OF TREATING ULCERATIVE COLITIS | ||
| Former [2021/07] | MÉTHODES DE TRAITEMENT DE LA COLITE ULCÉREUSE | Entry into regional phase | 30.10.2020 | National basic fee paid | 30.10.2020 | Designation fee(s) paid | 30.10.2020 | Examination fee paid | Examination procedure | 28.10.2020 | Amendment by applicant (claims and/or description) | 30.10.2020 | Examination requested [2021/07] | 30.10.2020 | Date on which the examining division has become responsible | 06.08.2021 | Despatch of a communication from the examining division (Time limit: M06) | 16.02.2022 | Reply to a communication from the examining division | 27.06.2022 | Despatch of a communication from the examining division (Time limit: M06) | 06.01.2023 | Reply to a communication from the examining division | 11.05.2023 | Communication of intention to grant the patent | 07.09.2023 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 04.10.2023 | Communication of intention to grant the patent | 05.02.2024 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 18.03.2024 | Communication of intention to grant the patent | 20.03.2024 | Fee for grant paid | 20.03.2024 | Fee for publishing/printing paid | 20.03.2024 | Receipt of the translation of the claim(s) | Divisional application(s) | EP23215626.5 / EP4327866 | EP25221972.0 | Opposition(s) | 11.02.2025 | No opposition filed within time limit [2025/16] | Fees paid | Renewal fee | 31.03.2021 | Renewal fee patent year 03 | 31.03.2022 | Renewal fee patent year 04 | 31.03.2023 | Renewal fee patent year 05 | 31.03.2024 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | SM | 08.05.2024 | [2025/10] | Cited in | International search | [I] US2017002060 (BOLEN JOSEPH BEENE et al.) | [I] US2012282269 (BARRETT RACHEL REBECCA et al.) | [I] WO2010062663 (SCHERING CORP et al.) | [I] US2007009526 (BENSON JACQUELINE et al.) | [I] MARIANGELA ALLOCCA ET AL: "Evolving strategies and goals of treatment in ulcerative colitis", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL GASTROENTEROLOGY, vol. 32-33, 1 February 2018 (2018-02-01), US, pages 1 - 2, XP055593398, ISSN: 1521-6918, DOI: 10.1016/j.bpg.2018.07.001 DOI: http://dx.doi.org/10.1016/j.bpg.2018.07.001 | [A] HANAN EL-BASSAT ET AL: "Interleukin-23p19 expression in patients with ulcerative colitis and its relation to disease severity", ADVANCES IN DIGESTIVE MEDICINE, vol. 3, no. 3, 8 September 2015 (2015-09-08), pages 88 - 94, XP055593338, ISSN: 2351-9800, DOI: 10.1016/j.aidm.2015.04.002 DOI: http://dx.doi.org/10.1016/j.aidm.2015.04.002 | by applicant | US7935344 | US8293883 | US8778346 | US9023358 | US8722033 | ORDAS ET AL., LANCET, vol. 380, no. 9853, 2012, pages 1606 - 1619 | BURGER D ET AL., GASTROENTEROLOGY, vol. 140, no. 6, 2011, pages 1827 - 1837 | KOPP T ET AL., NATURE, vol. 521, no. 7551, 2015, pages 222 - 226 | SANDS BE ET AL., JOURNAL OF CROHN'S AND COLITIS, vol. 9, no. 1, 2015, pages S15 - S16 | EL-BASSAT H ET AL., JOURNAL OF MOLECULAR BIOMARKERS & DIAGNOSIS, vol. 5, no. 5, 2014, pages 100191 | SCHROEDER ET AL., NEW ENG J MED, vol. 317, no. 26, 1987, pages 1625 - 1629 | COLLIGAN ET AL.: "Current Protocols in Immunology", 1994, JOHN WILEY & SONS | CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1350289-85-8 | CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1326244-10-3 | CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1612838-76-2 | CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1884201-71-1 | CHEMICAL ABSTRACTS, Columbus, Ohio, US; abstract no. 1610353-18-8 | A. GENNARO ET AL.: "Remington: The Science and Practice a/Pharmacy", 1995, MACK PUBLISHING CO. |